Immunotherapy drug shows promise for rare blood cancer relapses

NCT ID NCT03703050

First seen Apr 24, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This study tests the immunotherapy drug nivolumab in 45 children and adults with a rare type of blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to treatment. Participants either have active disease (to see if the drug shrinks tumors) or are in remission after a relapse (to see if it helps keep the cancer away). The goal is to control the disease, not cure it, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING/REFRACTORY ALK+ ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

  • CHU Bordeaux Hopital Pellegrin

    Bordeaux, 33076, France

  • CHU Mondor

    Créteil, France

  • CHU Toulouse Hopital des enfants

    Toulouse, 31059, France

  • CHU de nancy

    Vandœuvre-lès-Nancy, 54500, France

  • Centre Léon Berard Lyon

    Lyon, 69008, France

  • Centre Oscar Lambret

    Lille, France

  • Gustave Roussy

    Villejuif, Val de Marne, 94805, France

  • Hôpital Saint Louis

    Paris, 75010, France

  • Hôpital Trousseau

    Paris, Paris, 75012, France

  • IUC Toulouse

    Toulouse, 31059, France

  • Rigshospitalet

    Copenhagen, Denmark

  • Women'S and Children'S Nhs Foundation Trust

    Birmingham, United Kingdom

Conditions

Explore the condition pages connected to this study.